Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 NIrXVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nqW|IvPSEQvF2= NFSx[YgyNTRiZB?= M{S2e2ROW09? M1PHboVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv MXuyOVQ6ODN6Mx?=
H1703 NXHzcI02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrGSItVOi53IN88US=> MXKxMVQh\A>? NGixbVlFVVOR MXLlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKHS{ZXH0cYVvfCC5aYToJJRidW:6aX\lci=> M2\aWlI2PDlyM{iz
HUVECs MojwR5l1d3SxeHnjbZR6KEG|c3H5 NXHZfFV2OTByIH7N NEfj[HQzPCCq M2PYR4F1fGWwdXH0[ZMhfGinIHHido9o[XSrdnWg[YZn\WO2czDv[kBk[Wy7Y3;zbY4hd25iVmLJMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 M{S4S|I2PDVyMUi2
APRE-19 NHTpTJhCeG:ydH;zbZMhSXO|YYm= M2jCdFUh|ryP MnzYNlQhcA>? M{nzRoFjd2yrc3jld{BHVFpvbXXkbYF1\WRicILvMZN2en[rdnHsM4FvfGlvYYDvdJRwe2m|IHHjeIl3cXS7 MVuyOVMzQTZzNx?=
MDA-MB-231 NYf4dWs5SXCxcITvd4l{KEG|c3H5 MlHTNeKh|ryPwrC= MkX1OFghcA>? NETXdHNFVVOR MX7k[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygeJJm[XSnZDD3bZRpKDJ3IN88UUBw\iCIMTDvdkBHOiEEoB?= NGL1cFYzPTNyMEmzNi=>
MCF7 NEHYWYZHfW6ldHnvckBCe3OjeR?= NVHqW5kyOTByIH7N Mk\yNlQhcA>? NHPtTo1mdGmvaX7heIV{KEV{LXnu[JVk\WRiQWLFMWx2[yCjY4Tpeol1gQ>? MXSyOVE4OjV3Nx?=
HT-29  NVPrNoxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[1dGJiOS53wrFCuW0> Ml\4PVYhcA>? MVPk[YNz\WG|ZYOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHnubIljcXSnZDDifUBMYU6D M3PLd|I2ODF{MUKz
MO59K  NVHu[YNGS3m2b4TvfIlkcXS7IFHzd4F6 MYe1xsDPxE1? NHG5fJk4KGR? MnHXSG1UVw>? Ml3E[Y5p[W6lZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw NWSySXdnOjR7NUO1OlE>
MO59J Mk\BR5l1d3SxeHnjbZR6KEG|c3H5 MojkOeKh|ryP Mn36O{Bl M1\mfGROW09? NGnSZnpmdmijbnPld{B1cGViY4n0c5RwgGmlaYT5JI9nKGW2b4Dvd4ll\SCxcjDjbZNxdGG2aX6= M2m2ZlI1QTV|NU[x
MO59K  MXfBdI9xfG:|aYOgRZN{[Xl? NFnS[WoyOCEQvF2= M2DST|I1KGh? Ml\TSG1UVw>? NYLi[mYycW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw NFnHUZUzPDl3M{W2NS=>
MO59J M121OGFxd3C2b4Ppd{BCe3OjeR?= MkDuNVAh|ryP NYfkWFhZOjRiaB?= NVLpN25jTE2VTx?= MVjpcoNz\WG|ZYOgeIhmKESVQjDs[ZZmdCCrbnT1Z4VlKGK7IHX0c5Bwe2mmZTDvdkBkcXOybHH0bY4> M3LtS|I1QTV|NU[x
HepG2 MXHGeY5kfGmxbjDBd5NigQ>? M1jJUVExOCCwTR?= M3;CU|AvPSCq NHjVd3hFVVOR NGHEVmJjdG:la4OgUWEucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v NWL4PVdmOjR6NkOzOVA>
A549  M2L2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXM[2I{KML3TdMg NE\tXnYzKGh? NGX4ZWR{fXCycnXzd4V{KHCnbXX0doV5\WRvaX7keYNm\CCDa4SgZY5lKEeVS{ROtkBi[3SrdnH0bY9vNCCVLYDoZZNmKGG{cnXzeEwh[2WubDDhdI9xfG:|aYOgZY5lKGOjc4Dhd4UuOyCjY4TpeoF1cW:w M4HSb|I1QDR5OE[z
A549  M323ZmZ2dmO2aX;uJGF{e2G7 MlXkNVDDqM7:bdMg MlPLNVYhcA>? MmXSSG1UVw>? M1zUWI1w\HWuYYTld{B1cGViSVHWJJJmeGyrY3H0bY9vKGGwZDDjZZV{\XNicnX0[Y51cW:wIH;mJG5RKGmwIITo[UBvfWOuZYXzMi=> M1LRdFI1QDB{MUGx
SK-N-LO MljwSpVv[3Srb36gRZN{[Xl? NHWyem8yODBibl2= M{D2SFAvPSCq MlfM[IVkemWjc3XzJJRp\SC|dHnteYxidnRiZX\m[YN1eyCxZjDtc5JxcGmwZTDvckBCc3RicHjvd5Bpd3K7bHH0bY9v NI\xb2kzPDZ3NE[wOi=>
HL-60 NYXuPZI3TnWwY4Tpc44hSXO|YYm= M{j1clAvOcLizszN MYe3NkBp M3LzU4Jtd2OtczDkZZNifGmwaXKtbY5lfWOnZDDj[YxtKGSrZn\ldoVvfGmjdHnvci=> NIr2cHYzPDZyN{K3Ny=>
HepG2  NV;Qb5dITnWwY4Tpc44hSXO|YYm= M1\zXFIxOCCwTR?= NWPRU5BbOC53IHi= MUXheJRmdnWjdHXzJGZwgE9icHjvd5Bpd3K7bHH0bY9v M3KxdVI1PTN3MUmy
H520 NIjYem9HfW6ldHnvckBCe3OjeR?= NVmySo5MOTEEoN88US=> MlWzNUBp NFLIfGRFVVOR MYPk[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= NEDiVFAzPDR2N{mzOS=>
H1975 NGLBXHhHfW6ldHnvckBCe3OjeR?= M{XzTlExyqEQvF2= MlTDNUBp NWH3e2dRTE2VTx?= Ml3D[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz NGfxSnozPDR2N{mzOS=>
MG-63 NFTqemxCeG:ydH;zbZMhSXO|YYm= M{DaR|ExKML3TR?= NEfwelAyOiCq NWWxUm5U\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? MmHPNlQ{PTh|MEG=
5637 MWTBdI9xfG:|aYOgRZN{[Xl? M1;JZ|ExyqEQvF2= M4X6O|QxKG2rbh?= MUny[ZZmenOnczDwNlFYSUZzIHX4dJJme3Orb36sJGNFUyCneIDy[ZN{cW:wLDDhcoQh[2WubDDpcohq[mm2aX;uJIlv\HWlZXSgZpkh\nWlb3nkZY4> M4[zSFI1OzN|OE[4
HEK-293 NFe2XphHfW6ldHnvckBCe3OjeR?= Ml60NVUxdk1? MX2xOkBp NYnrbHNMTE2VTx?= M33lWIRm[3KnYYPld{BEWlRiYXP0bZZqfHl? MWKyOFMzPDN4Nh?=
SW480  MnzvSpVv[3Srb36gRZN{[Xl? NXKyc5doOTVybl2= NV3SSoJ7OjBiaB?= NXKxUWR1TE2VTx?= M3PpR5Jm\HWlZYOgZ4VtdHWuYYKgZYNkfW23bHH0bY9vKG:oIN8yMYNifGWwaX6= NWrFOIRTOjR|MkSzOlY>
HepG2 NGLTSY1HfW6ldHnvckBCe3OjeR?= NYj4TXRlOTByIH7N NEiwZXUzPCCq M2HqWoF1fGWwdXH0[ZMhfGinIHPvcI9vcWW|IH;mJJRp\SC2dX3vdkBk\WyuczD3bZRpKHWycnXneYxifGmxbjDv[kBCc3Rz MYCyOFI6PzVzMB?=
HCT 116  NH:3Uo1HfW6ldHnvckBCe3OjeR?= NWXC[Vl4OTByIH7N MmHFNlQhcA>? MoPMZZR1\W63YYTld{B1cGViY3;sc45q\XNib3[geIhmKHS3bX;yJINmdGy|IIfpeIghfXC{ZXf1cIF1cW:wIH;mJGFsfDF? MlHoNlQzQTd3MUC=
BEL/FU MnH6SpVv[3Srb36gRZN{[Xl? NXux[4lqOSCvTR?= MWGyOEBp NXrvdY5l\GWlcnXhd4V{KHC{b4TlbY4hdGW4ZXzzJI9nKHSqZTDQTVNMN0GtdDDwZZRpf2G7 M2i0PVI1OjN{MEm5
Huh7  MmXVSpVv[3Srb36gRZN{[Xl? MV2zxsDPxE1? MYCxJIg> MWPy[YR2[2W|IITo[UB3cXK3czDlcpRzgSCrboTvJJRp\SClZXzsdy=> MXGyOFE5PDF7Nh?=
A-375 NUfLfJFUSXCxcITvd4l{KEG|c3H5 MmTEOE85KM7:TR?= M1PtNFI1KGh? M1\VO4VvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= Ml62NlQyOTNzN{O=
A-375-TS  NVyzR4U1SXCxcITvd4l{KEG|c3H5 MUO0M|gh|ryP NIq1dIMzPCCq M3:5NYVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= M3naS|I1OTF|MUez
Mel-HO MkLrRZBweHSxc3nzJGF{e2G7 MUC0M|gh|ryP M{HqS|I1KGh? NUXje25q\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MVWyOFEyOzF5Mx?=
Mel-HO-TS MVPBdI9xfG:|aYOgRZN{[Xl? MoL6OE85KM7:TR?= NXP3NmFbOjRiaB?= NXLsNZJE\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NXi0Zm1SOjRzMUOxO|M>
MeWo NYPkWlFtSXCxcITvd4l{KEG|c3H5 M1j0V|QwQCEQvF2= NGHqPIgzPCCq MYflcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NELwOnQzPDFzM{G3Ny=>
Mel-2a NXnrPZNRSXCxcITvd4l{KEG|c3H5 MoToOE85KM7:TR?= M{nJN|I1KGh? MnnL[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= NUnLfpVDOjRzMUOxO|M>
MDA-MB-231 MmTHSpVv[3Srb36gRZN{[Xl? MoK1NQKBmzRyMDDuUS=> M4rFPVQhcA>? MVrzeZBxemW|c3XzJGFsfCCyaH;zdIhwenmuYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3:5XVIzQTB4MkW5
MDA-MB-231 Mm\rSpVv[3Srb36gRZN{[Xl? Mn;JOFAxKG6P MmTJOEBp NU\Pb5Bt\GWlcnXhd4V{KE2PUD25JIFv\CCLTD24JJBzd3SnaX6gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlnSNlI6ODZ{NUm=
Jurkat NEXjeXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2wMlI2NTFwMkWg{txO MWWyOE81QCCq NVrrN5R7TE2VTx?= MkDybY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? MXGxPVc2PzF6NR?=
Namalwa NWmzfoxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jZZlAvOjVvMT6yOUDPxE1? NIPGSZUzPC92ODDo NWThNVlETE2VTx?= NFG1T2RqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= MoPrNVk4PTdzOEW=
Jurkat MYnBdI9xfG:|aYOgRZN{[Xl? M{C3eVAvOjVvMT6yOUDPxE1? MX[yOE81QCCq MX;EUXNQ MofsbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy NIHiXIoyQTd3N{G4OS=>
Namalwa NVq1[|U4SXCxcITvd4l{KEG|c3H5 MlXONE4zPS1zLkK1JO69VQ>? NG\aVWMzPC92ODDo NYTKOo9VTE2VTx?= Mn\lbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy MUexPVc2PzF6NR?=
K562 NGrmTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCyOEBp MWrJR|UxRTJ3wsGwMlE1KG6P MmPNNVk3PjJ|NkG=
SW1990 M2DVdmZ2dmO2aX;uJGF{e2G7 NE\3WHExNjBzLUGg{txO Ml65NUBp NYTWcm93cW6qaXLpeJMhUEFvaX7keYNm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w MWGxPVQ3QTB{MB?=
RT112  NHnNbYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOxNOKh|ryP MXuyOEBp MUHEUXNQ MYPk[YNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gS|IwVSClZXzsdy=> NGTZSGQyQDd6N{izNi=>
MHG-U1 NWXXXHg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLxNVDDqM7:TR?= MVGyOEBp Ml7rSG1UVw>? NWXOT3BW\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKEd{L12gZ4VtdHN? NVvjenJ7OTh5OEe4N|I>
SMMC-7721 MY\BdI9xfG:|aYOgRZN{[Xl? M3rF[FIxOMLibl2= MmXSNlQhcA>? MX7pcoNz\WG|ZYOgR2hZNWmwZIXj[YQh[XCxcITvd4l{ NVrDWG5DOTd3NUexPVE>
SMMC-7721 M2nwXmZ2dmO2aX;uJGF{e2G7 NXXOb2t5OjBywrDuUS=> MYOyOEBp MoCxeZAuemWpdXzheIV{KM7{MTy0S3QyKGW6cILld5Nqd25? Mmj0NVc2PTdzOUG=
HeLa M1vK[mZ2dmO2aX;uJGF{e2G7 NGG2Z|MyODEEoH7NxsA> MYOxJIg> NVr3R3A1[Wy2ZYLzJJRp\SCvb4LwbI9td2e7IH;mJJRp\SC2cnHud4ZmenKrbjDy[YN6[2yrbnegZ49ueGG{dH3lcpQ> MVuxOlg6ODlzNR?=
MRC5VI NX[0fIo6TnWwY4Tpc44hSXO|YYm= MU[xNk42KG2P NWSzc4l7OC53IHi= MmHKSG1UVw>? M3TxeoFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NULtTIg2OTZ{MkezPVQ>
AT5BIVA NHTuOmJHfW6ldHnvckBCe3OjeR?= MkLYNVIvPSCvTR?= NIfzVmExNjViaB?= NHPK[W5FVVOR MWPhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> NWX6eFRoOTZ{MkezPVQ>
M059J MVfGeY5kfGmxbjDBd5NigQ>? M3PHVVEzNjVibV2= M{[3PVAvPSCq NITweJdFVVOR MnXOZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> NUTseoI5OTZ{MkezPVQ>
HeLa NWC0e49ITnWwY4Tpc44hSXO|YYm= MnHxNVIvPSCvTR?= MV6wMlUhcA>? NX\veZNWTE2VTx?= MkSwZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> M{L5Z|E3OjJ5M{m0
N2a NFfBXWhCeG:ydH;zbZMhSXO|YYm= NXLJSJJFOC5zLUGwJO69VQ>? MkTkNkBp NWrNN3VqcW6mdXPld{Bl\WO{ZXHz[YQh[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NF;2b4kyPTh2Mke2Oy=>
Jurkat  M2\sOWtqdmG|ZTDBd5NigQ>? NEfm[lRKSzVyIH;mJFI1KG6P MX2xOVY3PDVzOR?=

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID